A new off-the-shelf vaccine shows promising early results as a treatment for pancreatic cancer, targeting tumors with mutations in the KRAS gene. The vaccine, tested in a phase 1 trial, is found to be safe and effective in stimulating the immune system to create cancer-fighting cells in patients with pancreatic and colorectal cancer. The vaccine can potentially reduce tumor DNA in the blood and delay the recurrence of cancer. The future use of off-the-shelf vaccines could benefit more patients without the time and cost associated with personalized mRNA vaccines. Researchers are excited about the potential of these findings and believe they show promise for immune cell activation in targeting pancreatic cancer.
Source link
New vaccine may be potential off-the-shelf treatment for pancreatic, colorectal cancer
